Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Rapid Bone Loss Possible Side Effect of Anti-Obesity Drug

Published: Tuesday, February 07, 2012
Last Updated: Monday, February 06, 2012
Bookmark and Share
Research from UT Southwestern Medical Center has raised concern about the safe use of fibroblast growth factor 21.

An endocrine hormone used in clinical trials as an anti-obesity and anti-diabetes drug causes significant and rapid bone loss in mice,

The hormone, fibroblast growth factor 21 (FGF21), promotes bone loss by enhancing the activity of a protein that stimulates fat cells but inhibits bone cells, researchers report in a study available online in Proceedings of the National Academy of Sciences.

“This hormone is a very potent regulator of bone mass,” said Dr. Yihong Wan, assistant professor of pharmacology and senior author of the study. “When we oversupply FGF21 in mice, it results in substantial bone loss.”

UT Southwestern scientists had been investigating this hormone’s properties since its discovery in 2005 as a potential drug.

Bone loss was a side effect of another class of compounds that had been commonly used in the treatment of diabetes - activating the same protein in a manner similar to FGF21 - and leading the research team to investigate the bone effect of FGF21 in three kinds of mice.

They found that rodents fed a drug form of the hormone over a two-week period lost 78 percent of their spongy bone. Mice engineered to produce excess FGF21 had similar effects.

Conversely, researchers found mice completely lacking the hormone had comparable gains in bone mass.

While the insulin-sensitizing effects of FGF21 make it a potentially powerful anti-obesity drug, that could be canceled out by risk of osteoporosis and fractures associated with bone loss, the investigators report.

“The bone effect is clear,” said Dr. David Mangelsdorf, chairman of pharmacology, a Howard Hughes Medical Institute investigator at UT Southwestern and one of the study’s corresponding authors.

Dr. Mangelsdorf continued, “It’s a tradeoff of benefits and risks, and the key will be to design the drug in such a way to leverage the two against each other, dialing out the side effects and dialing in the positive.”

In a related study online in Cell, researchers at the medical center identified how FGF21 regulates the activity of a diabetes-fighting compound in fat tissue, altering metabolism in response to starvation and resumed eating for survival-driven energy conservation.

“FGF21 helps mobilize the fat in adipose tissue back to the liver and burn it. But when the animal is refed, it stops this process and immediately turns back to restoring fat. In one case, it turns this system on, and in the other, turns it off,” said Dr. Steven Kliewer, professor of molecular biology and pharmacology and senior author of the Cell paper.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Alzheimer’s Linked Protein Can Be Removed From Brain Without Hindering Memory, Learning
Researchers at UTSW have found that the mice can maintain their learning and memory when virtually all ApoE is removed from the brain but kept present in the liver to filter cholesterol.
Wednesday, October 05, 2016
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
Friday, September 30, 2016
UT Southwestern Targets Rising Rates of Kidney Cancer
Company has received $11 million in funding to the rising threat of kidney cancer.
Wednesday, August 03, 2016
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Friday, April 08, 2016
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
Thursday, March 31, 2016
Pcsk9-Inhibitor Drug Class That Grew out of UTSW Research Becomes a Game-Changer for Patient
Researchers at UTSW have developed a new pcsk9-inhibitor drug class that effective in reduced the high cholesterol level.
Friday, February 26, 2016
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Friday, January 22, 2016
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Saturday, January 16, 2016
Researchers Assist in Landmark NIH Study
Study shows intensive blood pressure management may save lives.
Saturday, September 12, 2015
Blocking DNA Repair Mechanisms Could Improve Brain Cancer Therapy
The findings were published April 7 in Nature Communications.
Saturday, April 12, 2014
Study Identifies Potential Therapeutic Target for Incurable, Rare Type of Soft-Tissue Cancer
UT Southwestern scientists study published online in Cell Reports.
Friday, December 27, 2013
Researchers Identify Novel Class of Drugs for Prostate Cancers
A new study on prostate cancer describes a novel class of drugs that interrupts critical signaling needed for prostate cancer cells to grow.
Wednesday, May 29, 2013
Experimental Drug Shows Promise Against Brain, Prostate Cancers, UT Southwestern Researchers Find
Study shows that drug attacked not only the bulk of the tumor cells but also the rare cancer stem cells responsible for cancer’s growth.
Wednesday, January 06, 2010
UT Southwestern Aids National Effort to Recruit Volunteers for Medical Research
A new national initiative will match volunteers who want to take part in medical research studies with the scientists who are leading those studies.
Thursday, November 19, 2009
UT Southwestern Researchers Use Drug-Radiation Combo to Eradicate Lung Cancer
Researchers have eliminated non-small cell lung cancer in mice by using an investigative drug called BEZ235 in combination with low-dose radiation.
Friday, November 06, 2009
Scientific News
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Skin Patch to Treat Peanut Allergy
NIH-funded study suggests peanut protein patch is a safe and convenient method of treatment.
NIH Contributes to Global Effort to Prevent and Manage Lung Diseases
The large scale trial will measure health benefits of clean cookstoves.
Anti-Inflammatory Drugs Could Help Treat Depression
Anti-inflammatory drugs could be used to treat some cases of depression, which further implicates our immune system in mental health disorders.
Questioning the Safety of Selenium to Combat Cancer
Research indicates the need for change in practice as selenium supplements cannot be recommended for preventing colorectal cancer.
Scientists at NIH and Emory Achieve Sustained SIV Remission in Monkeys
The finding suggest that the immune systems of these animals are controlling SIV replication in the absence of antiretroviral therapy.
Painting the Way to Tumour Imaging
Tumour paint used in emergency surgery to aid cell identification for surgeons.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
Targeting Estrogen Receptor Improves Survival in Breast Cancer
Trial finds estrogen receptor degrader significantly increases progression-free survival in patients with advanced breast cancer.
Clinical Trial Finds Medicine Program Alters Blood Serum
Meditation, yoga and vegetarian diet linked to decline in plasma metabolites associated with inflammation and cardiovascular disease risk.
Scroll Up
Scroll Down

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos